Skip to main content
OpenTrials

Clinical trial condition

Small Lymphocytic Lymphoma

Explore clinical trials studying Small Lymphocytic Lymphoma. Study availability and eligibility vary by location and protocol.

162 public trials 44 recruiting studies
Refine in advanced search Browse all conditions

Small Lymphocytic Lymphoma trial results

Active, Not Recruiting

Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

NCT03960840

Conditions
Acute Lymphoblastic Leukemia, Chronic Disease, Chronic Lymphocytic Leukemia, +23 more
Locations
  • University of California LA Los Angeles, California, United States
  • Stanford University Medical Center Stanford, California, United States
  • H Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Uni of Chi Medi Ctr Hema and Onco Chicago, Illinois, United States
View all 37 locations
View Trial Details
Active, Not Recruiting

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

NCT05718869

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
  • University of Miami Sylvester Comprehensive Cancer Center Miami, Florida, United States
View Trial Details
Active, Not Recruiting

ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia

NCT02029443

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +18 more
Locations
  • Research Site Boston, Massachusetts, United States
  • Research Site New Hyde Park, New York, United States
  • Research Site New York, United States
  • Research Site Columbus, Ohio, United States
View Trial Details
Active, Not Recruiting

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

NCT04666038

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +18 more
Locations
  • Southern Cancer Center, P.C. Daphne, Alabama, United States
  • Mitchell Cancer Institute -University of South Alabama Mobile, Alabama, United States
  • Palo Verde Hematology Oncology Glendale, Arizona, United States
  • Arizona Oncology Associates, P.C. - HOPE Tucson, Arizona, United States
View all 232 locations
View Trial Details
Active, Not Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details
Active, Not Recruiting

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

NCT02952508

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Central Nervous System Lymphoma, +36 more
Locations
  • Cellectar Biosciences site Los Angeles, California, United States
  • Cellectar Biosciences site Redlands, California, United States
  • Cellectar Biosciences site Washington D.C., District of Columbia, United States
  • Cellectar Biosciences site Jacksonville, Florida, United States
View all 52 locations
View Trial Details
Active, Not Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

NCT05624554

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Highlands Oncology Group ( Site 5205) Springdale, Arkansas, United States
  • Clermont Oncology Center ( Site 5224) Clermont, Florida, United States
  • Hattiesburg Clinic Hematology/Oncology ( Site 5216) Hattiesburg, Mississippi, United States
  • Medical Oncology Associates, PS ( Site 5206) Spokane, Washington, United States
View all 97 locations
View Trial Details
Active, Not Recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

NCT03336333

Conditions
Chronic Disease, Chronic Lymphocytic Leukemia, Disease Attributes, +15 more
Locations
  • Augusta University Augusta, Georgia, United States
  • Northwestern University Chicago, Illinois, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Research Medical Center Kansas City, Missouri, United States
View all 158 locations
View Trial Details

Related conditions